These mutations, as well as that of NRAS, on average activate spot E and thus the endothelial immune responsive LMS5 and, on the other hand, associate with the downregulation of proliferation and CIN characteristics (spot C and D, respectively) and of the epithelial signature (spot A) for mutated KRAS. The gene discussed is NRAS; the disease is cervical squamous intraepithelial neoplasia.